BridgeBio Oncology Therapeutics (BBOT) Cash & Equivalents (2024 - 2026)

BridgeBio Oncology Therapeutics has reported Cash & Equivalents for 3 years, with the latest figure at $52.7 million in Q1 2026.

• Quarterly Cash & Equivalents rose 5367.35% year-over-year to $52.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $52.7 million (up 5367.35% YoY) and the FY2025 annual result came in at $373.7 million, up 1111.26% from the prior year.
• Cash & Equivalents slipped to $52.7 million in Q1 2026 per BBOT's latest filing, from $373.7 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $408.7 million in Q3 2025 and troughed at $664231.0 in Q2 2025.
• A 3-year average of $97.0 million and a median of $1.8 million in 2024 frame the typical range for Cash & Equivalents.
• The widest YoY moves for Cash & Equivalents: up 22790.5% in 2025, down 63.39% in 2025.
• Over 3 years, Cash & Equivalents stood at $30.9 million in 2024, then soared by 1111.26% to $373.7 million in 2025, then sank by 85.91% to $52.7 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $52.7 million, $373.7 million, and $408.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.